IBONYSEPharmaceutical PreparationsFiscal year ends December 31
IMPACT BIOMEDICAL INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$3.06+0.38 (+14.18%)
Close on Oct 19, 2026
- Market cap
- $329.93M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
No earnings releases found
Impact Biomedical has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.
Press releases
Announcements Impact Biomedical filed with the SEC
Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Limited (f/k/a
Regulation FD disclosure · EX-99.1 to Form 8-K
— Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited
Regulation FD disclosure · EX-99.1 to Form 8-K
Ashleys Limited and Impact BioMedical Inc. Announce Strategic Merger
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
BioMedical Inc. Announces Pricing of Initial Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
BioMedical Inc. Announces the Closing of its Initial Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K